标题
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
作者
关键词
-
出版物
Cells
Volume 9, Issue 1, Pages 37
出版商
MDPI AG
发表日期
2019-12-23
DOI
10.3390/cells9010037
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Past, present and future perspectives in nonalcoholic fatty liver disease
- (2019) Arun J. Sanyal Nature Reviews Gastroenterology & Hepatology
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH
- (2019) Joost Boeckmans et al. PHARMACOLOGICAL RESEARCH
- The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
- (2018) Montserrat A. de la Rosa Rodriguez et al. BMC GENOMICS
- The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View
- (2018) Christina C. Lindenmeyer et al. Clinics in Liver Disease
- Organ/body-on-a-chip based on microfluidic technology for drug discovery
- (2018) Hiroshi Kimura et al. Drug Metabolism and Pharmacokinetics
- PPAR Agonists and Metabolic Syndrome: An Established Role?
- (2018) Margherita Botta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders
- (2018) Xavier Palomer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
- (2018) Nahum Mendez-Sanchez et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Genetics and epigenetics of NAFLD and NASH: Clinical impact
- (2018) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Preclinical models of non-alcoholic fatty liver disease
- (2018) Prasanna K. Santhekadur et al. JOURNAL OF HEPATOLOGY
- Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
- (2018) Thomas Jensen et al. JOURNAL OF HEPATOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease
- (2018) Mohammad Zarei et al. Molecular Metabolism
- A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis
- (2018) Maddalena Parafati et al. Disease Models & Mechanisms
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
- (2018) Fan Hong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease
- (2018) Xilin Li et al. TOXICOLOGY
- Recent Advances in Body-on-a-Chip Systems
- (2018) Jong Hwan Sung et al. ANALYTICAL CHEMISTRY
- The role of the microbiome in NAFLD and NASH
- (2018) Aleksandra A Kolodziejczyk et al. EMBO Molecular Medicine
- Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka
- (2018) Madunil Anuk Niriella et al. Hepatology International
- Non-alcoholic fatty liver disease – A global public health perspective
- (2018) Zobair M. Younossi JOURNAL OF HEPATOLOGY
- Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
- (2018) Zobair M. Younossi et al. TRANSPLANTATION
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Response to: Comment to “EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease”
- (2017) Giulio Marchesini et al. JOURNAL OF HEPATOLOGY
- Targeting the gut-liver axis in liver disease
- (2017) Reiner Wiest et al. JOURNAL OF HEPATOLOGY
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- Therapies in non-alcoholic steatohepatitis (NASH)
- (2017) Abdul M. Oseini et al. LIVER INTERNATIONAL
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Targeting nuclear receptors for the treatment of fatty liver disease
- (2017) Naoki Tanaka et al. PHARMACOLOGY & THERAPEUTICS
- A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response
- (2017) Alison Iroz et al. Cell Reports
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
- (2016) Manel Pladevall et al. BMC Cardiovascular Disorders
- Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
- (2016) Aleksander Skardal et al. DRUG DISCOVERY TODAY
- Drug-induced steatohepatitis
- (2016) Ajit Dash et al. Expert Opinion on Drug Metabolism & Toxicology
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Hepatic-specific PPARα-FGF21 action in NAFLD
- (2016) Elena Piccinin et al. GUT
- Combined effects of thePNPLA3rs738409,TM6SF2rs58542926, andMBOAT7rs641738 variants on NAFLD severity: a multicenter biopsy-based study
- (2016) Marcin Krawczyk et al. JOURNAL OF LIPID RESEARCH
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
- (2016) Barbara Gross et al. Nature Reviews Endocrinology
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
- (2016) Xiaomeng Feng et al. MEDICAL SCIENCE MONITOR
- A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout
- (2016) Jeffrey Poiley et al. Arthritis & Rheumatology
- Non-alcoholic fatty liver and the gut microbiota
- (2016) Stavros Bashiardes et al. Molecular Metabolism
- Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode
- (2016) Davide Capelli et al. Scientific Reports
- Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study
- (2015) V. W.-S. Wong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- De novolipogenesis in the liver in health and disease: more than just a shunting yard for glucose
- (2015) Francis W. B. Sanders et al. BIOLOGICAL REVIEWS
- Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study
- (2015) Sun Hwa Kim et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
- (2015) Guillaume Lassailly et al. GASTROENTEROLOGY
- PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
- (2015) Sven Francque et al. JOURNAL OF HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Inflammasome activation and function in liver disease
- (2015) Gyongyi Szabo et al. Nature Reviews Gastroenterology & Hepatology
- Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
- (2015) Hong-Mei Yan et al. PLoS One
- The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2
- (2015) Christopher Day et al. SEMINARS IN LIVER DISEASE
- Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
- (2015) Sosale Aravind Sosale et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway
- (2015) Ning Zhang et al. Oncotarget
- The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects
- (2014) Rémy Hanf et al. Diabetes & Vascular Disease Research
- The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease
- (2014) Wajahat Zafar Mehal DIGESTIVE DISEASES
- Gut microbiome and nonalcoholic fatty liver diseases
- (2014) Lixin Zhu et al. PEDIATRIC RESEARCH
- Chimeric Mice with Hepatocyte-humanized Liver as an Appropriate Model to Study Human Peroxisome Proliferator–activated Receptor-α
- (2014) Chise Tateno et al. TOXICOLOGIC PATHOLOGY
- PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells
- (2014) Alexandra Rogue et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
- (2013) Paola Dongiovanni et al. CURRENT PHARMACEUTICAL DESIGN
- High Rates of Fructose Malabsorption Are Associated with Reduced Liver Fat in Obese African Americans
- (2013) Ryan W. Walker et al. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress
- (2012) Miguel A. Lanaspa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Morphological and microarray analyses of human hepatocytes from xenogeneic host livers
- (2012) Chise Tateno et al. LABORATORY INVESTIGATION
- PPARs: Fatty acid sensors controlling metabolism
- (2012) Lars la Cour Poulsen et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
- (2011) Yun-Jung Choi et al. ATHEROSCLEROSIS
- Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity
- (2011) Esther M. M. Ooi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
- (2011) Harold E. Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis
- (2011) Suzanne E. Mahady et al. JOURNAL OF HEPATOLOGY
- Development of Novel Combination Therapies
- (2011) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glitazones for human nonalcoholic steatohepatitis
- (2011) Raluca Pais et al. Therapeutic Advances in Gastroenterology
- Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome
- (2010) Mark J. Dekker et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
- (2010) P. Dongiovanni et al. GUT
- Endogenous Ligands for Nuclear Receptors: Digging Deeper
- (2010) Michael Schupp et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Down-regulation of SREBP-1c is associated with the development of burned-out NASH
- (2010) Tadanobu Nagaya et al. JOURNAL OF HEPATOLOGY
- The role of the gut microbiota in nonalcoholic fatty liver disease
- (2010) Ahmed Abu-Shanab et al. Nature Reviews Gastroenterology & Hepatology
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation
- (2010) Anne Bugge et al. PPAR Research
- Peroxisome Proliferator-Activated Receptor Alpha Target Genes
- (2010) Maryam Rakhshandehroo et al. PPAR Research
- The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator-1 β in the Pathogenesis of Fructose-Induced Insulin Resistance
- (2009) Yoshio Nagai et al. Cell Metabolism
- Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
- (2009) Cindy J. Rubin et al. Diabetes & Vascular Disease Research
- A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans
- (2009) A. Kotronen et al. DIABETOLOGIA
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
- (2009) Luca Miele et al. HEPATOLOGY
- Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
- (2009) Vlad Ratziu et al. HEPATOLOGY
- A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis
- (2009) Shaoqing He et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice
- (2009) Maaike H. Oosterveer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The role of PPARα in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARα actions
- (2009) Michung Yoon PHARMACOLOGICAL RESEARCH
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
- (2008) Vlad Ratziu et al. GASTROENTEROLOGY
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
- (2008) Stefano Romeo et al. NATURE GENETICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started